SCHEMBL135428

SCHEMBL135428

CCCCCCCCOS(=O)(=O)OCCCCCCCC.[NaH]

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 15/20 0.64
CA2 P00918 15/20 0.64
CA9 Q16790 13/20 0.64
CA12 O43570 4/20 0.64
CA7 P43166 4/20 0.64
CA14 Q9ULX7 4/20 0.64
CA3 P07451 3/20 0.64
CA4 P22748 3/20 0.64
CA6 P23280 3/20 0.64
CA5A P35218 3/20 0.64
CA5B Q9Y2D0 3/20 0.64
RECQL P46063 2/20 0.61
TSHR P16473 2/20 0.61
GLA P06280 1/20 0.61
HPGD P15428 1/20 0.61
MAPK1 P28482 1/20 0.61
EPHX2 P34913 1/20 0.61
BLM P54132 1/20 0.61
KDM4E B2RXH2 1/20 0.46
USP2 O75604 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28627781 1.00 CA1 (0.64) CA1CA2CA9CA12CA7
SCHEMBL28358597 1.00 CA1 (0.64) CA1CA2CA9CA12CA7
SCHEMBL28922483 1.00 CA1 (0.64) CA1CA2CA9CA12CA7
SCHEMBL3100937 1.00 CA1 (0.64) CA1CA2CA9CA12CA7
SCHEMBL6129804 1.00 CA1 (0.64) CA1CA2CA9CA12CA7
SCHEMBL28354945 1.00 CA1 (0.64) CA1CA2CA9CA12CA7
SCHEMBL17336095 1.00 CA1 (0.64) CA1CA2CA9CA12CA7
SCHEMBL5677448 1.00 CA1 (0.64) CA1CA2CA9CA12CA7
SCHEMBL22289152 1.00 CA1 (0.64) CA1CA2CA9CA12CA7
SCHEMBL39943 1.00 CA1 (0.64) CA1CA2CA9CA12CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106865676-A A kind of sewage water treatment method 宁波诺丁汉大学 2017-06-20 CN disclosed
EP-2832730-A1 MIRABEGRON-CONTAINING PHARMACEUTICAL COMPOSITION Astellas Pharma Inc. (JP) 2015-02-04 EP disclosed
US-20150031734-A1 PHARMACEUTICAL COMPOSITION CONTAINING MIRABEGRON ASTELLAS PHARMA INC. (JP) 2015-01-29 US disclosed
CN-102946903-B High concentration antibody formulations AMGEN INC 2014-11-26 CN disclosed
CN-102946903-A High concentration antibody formulations AMGEN INC 2013-02-27 CN disclosed
US-20120058974-A1 Composition comprising pesticide and benzotriazole UV absorbers BASF SE (DE) 2012-03-08 US disclosed
US-7811605-B2 Method of formation of shape-retentive aggregates of gel particles and their uses ULURU INC. (US) 2010-10-12 US disclosed
US-20080063716-A1 METHOD OF FORMATION OF SHAPE-RETENTIVE AGGREGATES OF GEL PARTICLES AND THEIR USES ULURU INC. 2008-03-13 US disclosed
CN-101065109-A Method of formation of shape-retentive aggregates of gel particles and their uses ULURU INC (US) 2007-10-31 CN disclosed
EP-1814522-A1 METHOD OF FORMATION OF THE SHAPE-RETENTIVE AGGREGATES OF GEL PARTICLES AND THEIR USES Uluru Inc. (US) 2007-08-08 EP disclosed
CN-1521201-A Waterproof ventilated microporous membrane, its preparing method and use 上海杰事杰新材料股份有限公司 2004-08-18 CN disclosed
US-6117975-A AMINO ACID AND NUCLEOTIDE SEQUENCES; FOR THERAPY THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2000-09-12 US disclosed
US-5869257-A NUCLEIC ACID INDICATOR FOR DETERMINING THE EXPRESSION OF MELANOCORTIN-4 RECEPTORS BY HYBRIDIZATION TO COMPLEMENTARY SEQUENCE; PHYSIOLOGICAL THERAPY INVOLVING ORGANS AND TISSUES EXPRESSING RECEPTOR; DRUG SCREENING THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1999-02-09 US disclosed
US-5817787-A Probes and methods for detecting melanocortin-5 receptor THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1998-10-06 US disclosed
US-5710265-A GENETIC ENGINEERING; POLYPEPTIDES THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1998-01-20 US disclosed
US-5703220-A MAY BE USED TO PROVIDE THERAPEUTIC VEHICLES FOR TREATMENT OF PROCESSES INVOLVING FUNCTION OF MELANOCORTIN RECEPTORS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1997-12-30 US disclosed
US-5622860-A GENETIC ENGINEERING THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1997-04-22 US disclosed
EP-0000082-B1 PROCESS FOR IMAGE-WISE MODIFYING THE SURFACE OF AN ETCHABLE SUPPORT AND MATERIAL SUITABLE THEREFOR COMPRISING A COLLOID LAYER CONTAINING POLYMERS WITH OXIME-ESTER GROUPS AGFA-GEVAERT N.V. (BE) 1982-07-21 EP disclosed
US-4202697-A Production of etch-resist colloid and material suitable therefor AGFA-GEVAERT N.V. (BE) 1980-05-13 US disclosed
EP-0000082-A1 Process for image-wise modifying the surface of an etchable support and material suitable therefor comprising a colloid layer containing polymers with oxime-ester groups AGFA-GEVAERT N.V. (BE) 1978-12-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058974-A1 Composition comprising pesticide and benzotriazole UV absorbers DDT, CRY1, PAH CA1 1176/4885CA2 1381/4885CA9 3100/4885
US-20150031734-A1 PHARMACEUTICAL COMPOSITION CONTAINING MIRABEGRON GCGR, GPR119, GLP1R CA1 4633/4885CA2 3483/4885CA9 2931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.